ルモス・ファーマに関するコメント

$ルモス・ファーマ(LUMO.US)$ Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042

$ルモス・ファーマ(LUMO.US)$ © Reuters. Lumos Pharma (ticker: NASDAQ:LUMO) has announced promising top-line results from its OraGrowtH210 and OraGrowtH212 trials for LUM-201, highlighting its potential as an oral treatment for pediatric growth hormone deficiency (PGHD). The company detailed plans for future trials and regulatory discussions during its recent earnings call. With $36.1 million in cash at the end of 2023, Lumos Pharma is funded through Q3 2024 and is actively exploring partnership...

$ルモス・ファーマ(LUMO.US)$
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

$ルモス・ファーマ(LUMO.US)$ The company reported quarterly sales of $7.00 thousand which missed the analyst consensus estimate of $320.00 thousand by 97.81 percent. This is a 98.59 percent decrease over sales of $497.00 thousand the same period last year.

$ルモス・ファーマ(LUMO.US)$ Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
•OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD Population
•Delta at 6 and 12-month AHV Between Optima...